Avalon GloboCare Corp. (ALBT)

NASDAQ: ALBT · IEX Real-Time Price · USD
0.320
+0.018 (5.79%)
At close: Mar 28, 2024, 3:59 PM
0.318
-0.002 (-0.56%)
After-hours: Mar 28, 2024, 7:58 PM EDT

Company Description

Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and China.

The company develops and delivers transformative cellular therapeutics, precision diagnostics, and clinical laboratory services.

Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells.

It is also developing mRNA-based Flash-CAR cell therapy platform. In addition, the company develops Avalon clinical-grade tissue-specific exosome (ACTEX); AVA-Trap, a therapeutic program provides an effective therapeutic option to combat COVID-19 and other life-threatening conditions involving cytokine storms; offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited.

Avalon GloboCare Corp. has strategic partnership with HydroPeptide, LLC to engage in co-development and commercialization of a series of clinical-grade, exosome-based cosmeceutical, and orthopedic products; and corporate research agreement with the University of Pittsburgh of the Commonwealth System of Higher Education.

The company was founded in 2016 and is headquartered in Freehold, New Jersey.

Avalon GloboCare Corp.
Avalon GloboCare logo
Country United States
Founded 2014
Industry Real Estate Services
Sector Real Estate
Employees 5
CEO Dr. David K. Jin M.D., Ph.D.

Contact Details

Address:
4400 Route 9, Suite 3100
Freehold, New Jersey 07728
United States
Phone 732-780-4400
Website avalon-globocare.com

Stock Details

Ticker Symbol ALBT
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001630212
ISIN Number US05344R2031
Employer ID 47-1685128
SIC Code 2836

Key Executives

Name Position
Dr. David K. Jin M.D., Ph.D. Chief Executive Officer, President and Director
Luisa Ingargiola Chief Financial Officer
Meng Li Chief Operating Officer, Chief Marketing Officer and Secretary

Latest SEC Filings

Date Type Title
Mar 27, 2024 8-K Current Report
Jan 25, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Nov 22, 2023 8-K Current Report
Nov 14, 2023 10-Q Quarterly Report
Nov 9, 2023 8-K Current Report
Oct 20, 2023 D Notice of Exempt Offering of Securities
Oct 13, 2023 8-K Current Report
Oct 13, 2023 8-K Current Report
Sep 8, 2023 ARS Filing
Sep 8, 2023 DEF 14A Other definitive proxy statements